These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6137601)

  • 61. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aldose reductase inhibition: studies with alrestatin.
    Gabbay KH; Spack N; Loo S; Hirsch HJ; Ackil AA
    Metabolism; 1979 Apr; 28(4 Suppl 1):471-6. PubMed ID: 122298
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ; Honigsberger L; Ellis SH; Hardman M; Nattrass M
    Diabet Med; 1992 Jun; 9(5):463-8. PubMed ID: 1611835
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early retinal microangiopathy: prevention with aldose reductase inhibitors.
    Robison WG; Kador PF; Kinoshita JH
    Diabet Med; 1985 May; 2(3):196-9. PubMed ID: 2952420
    [No Abstract]   [Full Text] [Related]  

  • 70. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
    Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
    J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
    [No Abstract]   [Full Text] [Related]  

  • 73. [Prevention of experimental diabetic corneal endotheliopathy with aldose reductase inhibitor].
    Akagi Y; Takahashi Y; Tanabe T; Ikebe H; Majima K; Miyatani H; Miyamoto Y; Terubayashi H
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):187-93. PubMed ID: 3111199
    [No Abstract]   [Full Text] [Related]  

  • 74. Effects of sorbinil, dietary myo-inositol supplementation, and insulin on resolution of neuroaxonal dystrophy in mesenteric nerves of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Coleman BD; Williamson JR; Tilton RG
    Diabetes; 1991 May; 40(5):574-82. PubMed ID: 1902427
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R
    Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
    Chalk C; Benstead TJ; Moore F
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD004572. PubMed ID: 17943821
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of aldose reductase inhibitors on the progression of nerve damage.
    Greene DA; Sima AA
    Diabet Med; 1993; 10 Suppl 2():31S-32S. PubMed ID: 8334837
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.